Abstract
Summary
IVD Antibody
LPI (LP Information)' newest research report, the “IVD Antibody Industry Forecast” looks at past sales and reviews total world IVD Antibody sales in 2022, providing a comprehensive analysis by region and market sector of projected IVD Antibody sales for 2023 through 2029. With IVD Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world IVD Antibody industry.
This Insight Report provides a comprehensive analysis of the global IVD Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on IVD Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global IVD Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for IVD Antibody and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global IVD Antibody.
The global IVD Antibody market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for IVD Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for IVD Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for IVD Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key IVD Antibody players cover BD PharMingen, Abcam, R&D Systems, Cell Signaling Technology, Affymatrix, BioLegend, Santa Cruz Biotechnologies, Beckman Coulter and Roche/Ventana, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of IVD Antibody market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
mAb
pAb
rAbs
Segmentation by application
RIA
ELISA
CLIA
LFIA
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BD PharMingen
Abcam
R&D Systems
Cell Signaling Technology
Affymatrix
BioLegend
Santa Cruz Biotechnologies
Beckman Coulter
Roche/Ventana
Key Questions Addressed in this Report
What is the 10-year outlook for the global IVD Antibody market?
What factors are driving IVD Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do IVD Antibody market opportunities vary by end market size?
How does IVD Antibody break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “IVD Antibody Industry Forecast” looks at past sales and reviews total world IVD Antibody sales in 2022, providing a comprehensive analysis by region and market sector of projected IVD Antibody sales for 2023 through 2029. With IVD Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world IVD Antibody industry.
This Insight Report provides a comprehensive analysis of the global IVD Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on IVD Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global IVD Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for IVD Antibody and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global IVD Antibody.
The global IVD Antibody market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for IVD Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for IVD Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for IVD Antibody is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key IVD Antibody players cover BD PharMingen, Abcam, R&D Systems, Cell Signaling Technology, Affymatrix, BioLegend, Santa Cruz Biotechnologies, Beckman Coulter and Roche/Ventana, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of IVD Antibody market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
mAb
pAb
rAbs
Segmentation by application
RIA
ELISA
CLIA
LFIA
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BD PharMingen
Abcam
R&D Systems
Cell Signaling Technology
Affymatrix
BioLegend
Santa Cruz Biotechnologies
Beckman Coulter
Roche/Ventana
Key Questions Addressed in this Report
What is the 10-year outlook for the global IVD Antibody market?
What factors are driving IVD Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do IVD Antibody market opportunities vary by end market size?
How does IVD Antibody break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global IVD Antibody Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for IVD Antibody by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for IVD Antibody by Country/Region, 2018, 2022 & 2029
2.2 IVD Antibody Segment by Type
2.2.1 mAb
2.2.2 pAb
2.2.3 rAbs
2.3 IVD Antibody Sales by Type
2.3.1 Global IVD Antibody Sales Market Share by Type (2018-2023)
2.3.2 Global IVD Antibody Revenue and Market Share by Type (2018-2023)
2.3.3 Global IVD Antibody Sale Price by Type (2018-2023)
2.4 IVD Antibody Segment by Application
2.4.1 RIA
2.4.2 ELISA
2.4.3 CLIA
2.4.4 LFIA
2.4.5 Other
2.5 IVD Antibody Sales by Application
2.5.1 Global IVD Antibody Sale Market Share by Application (2018-2023)
2.5.2 Global IVD Antibody Revenue and Market Share by Application (2018-2023)
2.5.3 Global IVD Antibody Sale Price by Application (2018-2023)
3 Global IVD Antibody by Company
3.1 Global IVD Antibody Breakdown Data by Company
3.1.1 Global IVD Antibody Annual Sales by Company (2018-2023)
3.1.2 Global IVD Antibody Sales Market Share by Company (2018-2023)
3.2 Global IVD Antibody Annual Revenue by Company (2018-2023)
3.2.1 Global IVD Antibody Revenue by Company (2018-2023)
3.2.2 Global IVD Antibody Revenue Market Share by Company (2018-2023)
3.3 Global IVD Antibody Sale Price by Company
3.4 Key Manufacturers IVD Antibody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers IVD Antibody Product Location Distribution
3.4.2 Players IVD Antibody Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for IVD Antibody by Geographic Region
4.1 World Historic IVD Antibody Market Size by Geographic Region (2018-2023)
4.1.1 Global IVD Antibody Annual Sales by Geographic Region (2018-2023)
4.1.2 Global IVD Antibody Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic IVD Antibody Market Size by Country/Region (2018-2023)
4.2.1 Global IVD Antibody Annual Sales by Country/Region (2018-2023)
4.2.2 Global IVD Antibody Annual Revenue by Country/Region (2018-2023)
4.3 Americas IVD Antibody Sales Growth
4.4 APAC IVD Antibody Sales Growth
4.5 Europe IVD Antibody Sales Growth
4.6 Middle East & Africa IVD Antibody Sales Growth
5 Americas
5.1 Americas IVD Antibody Sales by Country
5.1.1 Americas IVD Antibody Sales by Country (2018-2023)
5.1.2 Americas IVD Antibody Revenue by Country (2018-2023)
5.2 Americas IVD Antibody Sales by Type
5.3 Americas IVD Antibody Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC IVD Antibody Sales by Region
6.1.1 APAC IVD Antibody Sales by Region (2018-2023)
6.1.2 APAC IVD Antibody Revenue by Region (2018-2023)
6.2 APAC IVD Antibody Sales by Type
6.3 APAC IVD Antibody Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe IVD Antibody by Country
7.1.1 Europe IVD Antibody Sales by Country (2018-2023)
7.1.2 Europe IVD Antibody Revenue by Country (2018-2023)
7.2 Europe IVD Antibody Sales by Type
7.3 Europe IVD Antibody Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa IVD Antibody by Country
8.1.1 Middle East & Africa IVD Antibody Sales by Country (2018-2023)
8.1.2 Middle East & Africa IVD Antibody Revenue by Country (2018-2023)
8.2 Middle East & Africa IVD Antibody Sales by Type
8.3 Middle East & Africa IVD Antibody Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of IVD Antibody
10.3 Manufacturing Process Analysis of IVD Antibody
10.4 Industry Chain Structure of IVD Antibody
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 IVD Antibody Distributors
11.3 IVD Antibody Customer
12 World Forecast Review for IVD Antibody by Geographic Region
12.1 Global IVD Antibody Market Size Forecast by Region
12.1.1 Global IVD Antibody Forecast by Region (2024-2029)
12.1.2 Global IVD Antibody Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global IVD Antibody Forecast by Type
12.7 Global IVD Antibody Forecast by Application
13 Key Players Analysis
13.1 BD PharMingen
13.1.1 BD PharMingen Company Information
13.1.2 BD PharMingen IVD Antibody Product Portfolios and Specifications
13.1.3 BD PharMingen IVD Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 BD PharMingen Main Business Overview
13.1.5 BD PharMingen Latest Developments
13.2 Abcam
13.2.1 Abcam Company Information
13.2.2 Abcam IVD Antibody Product Portfolios and Specifications
13.2.3 Abcam IVD Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Abcam Main Business Overview
13.2.5 Abcam Latest Developments
13.3 R&D Systems
13.3.1 R&D Systems Company Information
13.3.2 R&D Systems IVD Antibody Product Portfolios and Specifications
13.3.3 R&D Systems IVD Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 R&D Systems Main Business Overview
13.3.5 R&D Systems Latest Developments
13.4 Cell Signaling Technology
13.4.1 Cell Signaling Technology Company Information
13.4.2 Cell Signaling Technology IVD Antibody Product Portfolios and Specifications
13.4.3 Cell Signaling Technology IVD Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Cell Signaling Technology Main Business Overview
13.4.5 Cell Signaling Technology Latest Developments
13.5 Affymatrix
13.5.1 Affymatrix Company Information
13.5.2 Affymatrix IVD Antibody Product Portfolios and Specifications
13.5.3 Affymatrix IVD Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Affymatrix Main Business Overview
13.5.5 Affymatrix Latest Developments
13.6 BioLegend
13.6.1 BioLegend Company Information
13.6.2 BioLegend IVD Antibody Product Portfolios and Specifications
13.6.3 BioLegend IVD Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 BioLegend Main Business Overview
13.6.5 BioLegend Latest Developments
13.7 Santa Cruz Biotechnologies
13.7.1 Santa Cruz Biotechnologies Company Information
13.7.2 Santa Cruz Biotechnologies IVD Antibody Product Portfolios and Specifications
13.7.3 Santa Cruz Biotechnologies IVD Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Santa Cruz Biotechnologies Main Business Overview
13.7.5 Santa Cruz Biotechnologies Latest Developments
13.8 Beckman Coulter
13.8.1 Beckman Coulter Company Information
13.8.2 Beckman Coulter IVD Antibody Product Portfolios and Specifications
13.8.3 Beckman Coulter IVD Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Beckman Coulter Main Business Overview
13.8.5 Beckman Coulter Latest Developments
13.9 Roche/Ventana
13.9.1 Roche/Ventana Company Information
13.9.2 Roche/Ventana IVD Antibody Product Portfolios and Specifications
13.9.3 Roche/Ventana IVD Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Roche/Ventana Main Business Overview
13.9.5 Roche/Ventana Latest Developments
14 Research Findings and Conclusion